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Background: Controversy exists regarding the role of PD1 and its ligand PD-L1 in chronic hepatitis B infection. In
some studies, persistent HBV infection has been attributed to high levels of PD-1 and PD-L1 expression on
HBV-specific T-cells and antigen-presenting cells (APCs) respectively. Other studies revealed that the up-regulation
of PD-1 and PD-L1 during an acute inflammation phase is required to offset increasing positive co-stimulatory
signals to avoid severe damage by an over-vigorous immune response.
Methods: Fifteen chronic hepatitis B patients, with inflammatory flare episode, were recruited prospectively. Based
on serum HBV-DNA, HBsAg load, and ALT values, inflammatory flare episode were divided into initial, climax,
decline and regression phase. Blood sample and liver biopsy tissues from each individual were taken in these 4
phases respectively. Circulating and intra-hepatic PD1 and PD-L1 expression levels were monitored throughout the
inflammatory flare episode by flow cytometry and immunostaining and these expression levels were related to the
HBV-specific T-cell changes, expression of pro-inflammatory cytokines, HBV-DNA replication and HBV antigen load.
Results: ]The levels of PD-1 and PD-L1 expressions were significantly up-regulated in the inflammation ascending
phase, initial and climax period and in parallel with HBV-specific colon expansion. It showed increasing the level of
serum ALT and decreasing the HBV-DNA loads. As the level of inflammation reduced, the circulating and
intra-hepatic PD1 and circulating PD-L1 decreased progressively in concordance with serum ALT, HBV-DNA and HBsAg
loads decreased except intra-hepatic PD-1 expression. Intra-hepatic PD-L1 expression did not decrease significantly
during the regression phase of inflammation compared to that in prior period. The intra-hepatic PD-L1 expression
remained relatively on higher level when serum HBV-DNA load and ALT decreased to approximately normal range.
Conclusion: The relatively high level of intra-hepatic PD-L1 expression during the inflammatory regression period may
contribute to constitute an immunosuppressive microenvironment, which facilitate persistent HBV infection via the
inhibition of HBV-specific T cell clonal expansion.
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Hepatitis B virus (HBV) infection results in the het-
erogeneous diseases states that vary greatly in HBV
replication, liver pathology damage and outcome from
person to person. Some patients control infection effi-
ciently and are able to eliminate the virus either without
developing evident liver inflammation or a self-limited* Correspondence: shusenzheng@zju.edu.cn
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reproduction in any medium, provided the oracute hepatitis syndrome that resolves without long-
term periodic inflammatory episodes. Other patients
are unable to clear the virus and develop persistent
HBV infection.
Anecdotal evidence from clinical observation has
shown that the chronic hepatitis B infection often mani-
fests clinically with repeated inflammatory episodes
marked by fluctuating levels of serum ALT and HBV-
DNA. Levels of serum HBV-DNA and HBV antigens
load progressively decrease throughout the inflammatory
flare. During immune inactive period, HBV antigensLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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level to trigger another round of inflammation.
In recent studies, the inability to eliminate virus in
patients with chronic hepatitis B has been attributed to
high levels of expression of programmed death 1 (PD-1)
and its ligand (PD-L1/B7-H1) on viral antigen-specific
T-cells and antigen -presenting cells (APCs) respectively
[1-9]. The interaction between this pair of co-inhibitory
molecules has been shown to contribute directly to
T-cell dysfunction and poor control of viral replication.
Blocking the PD-1/PD-L1 interaction in vitro reversed
exhausted cytokine production and proliferation of
these HBV-specific T cells [1,4-6]. Thus, up-regulation
of PD1 and PD-L1 are generally considered markers of
malfunction of the HBV-specific immune response.
In contrast, other studies revealed that negative co-
stimulatory molecules play a key role in maintenance of
homeostasis [10,11]. Studies showed that delayed up
regulation of PD1 and PD-L1 were attributed to fulmi-
nant liver inflammation in patients with acute hepatitis
B and finally led to acute liver failure [12-14]. Previous
studies revealed that in patients with acute hepatitis B,
PD-L1 expression levels were up regulated during the
ascending phase of inflammation and decreased when in-
flammation regressed. This phenomenon suggested that a
balance exists between the negative and positive co-
stimulatory molecules on activated immune cells.
In order to elucidate the role of PD1 and PD-L1 in the
hepatitis B immune response, the relationship between
the PD1/ PD-L1 expression and immune response events,
such as HBV-specific CD8 T-cell expansion and contrac-
tion, pro-inflammatory cytokines expression, viral load,
and disease pathogenesis should be analyzed.
The majority of previous studies of the PD1 and PD-L1
expression in chronic hepatitis B patients were retrospect-
ive and cross-sectional. In this study, patients were en-
rolled prospectively and inflammatory flare period were
divided into initial, climax, decline and regression phase.
This study is novelty in its prospective and longitudinal
analysis of PD1 and PD-L1 expression in chronic hepatitis
B patients throughout inflammatory flare period.
The results showed that PD-1/PD-L1 expression was sig-
nificantly up-regulated during the inflammatory climax
period. During the regression period, when serum ALT de-
crease to approximately normal levels, intra-hepatic PD-L1
expression on Kupffer cells did not decrease significantly
compared to that in prior phase. These data suggest that
the relatively high level of intra-hepatic PD-L1 expression
during the inflammatory regression period may contribute
to constitute an immunosuppressive microenvironment.
The immunosuppressive microenvironment in liver may
facilitate persistent HBV infection via the transmission of
co-inhibitory signals to activated T-cells, and finally lead to
the next round of liver inflammation.Methods
Subjects
Chronic hepatitis B patients were followed-up in the out-
patient clinic by detection of serum ALT, HBV-DNA and
HBs-Ag load. Subjects who developed hepatitis B flare epi-
sode during follow up period were enrolled in this study.
Serum HBV-DNA load more than 5× 103 copies/mL , and
serum ALT level near to 5 times the upper limit of nor-
mal, were considered as the onset of initiation of inflam-
mation. HBV tolerance patients and fulminant hepatitis B
patients were excluded from this study. The recruiting
work was stopped when the fifteenth patient was enrolled.
Each of these fifteen patients was followed with protocol
visit for a median period of 4 months (range, 3–5 months).
Liver biopsy was performed according to ultrasound guide
in appointed time point as mentioned following:
Written informed consent was obtained from each en-
rolled patient, and the study protocol was approved by
the Ethics Committee of our unit. Reports of all patients
were negative for anti-hepatitis D virus antibodies, anti-
hepatitis C virus (anti-HCV) antibodies, anti-HIV1,2
antibodies, and auto-antibodies. The clinical data of
these enrolled patients at the first time point (initial
phase of inflammation) are summarized in Table 1.
Heparinized blood samples used for the separation of
peripheral blood mononuclear cells (PBMCs) and liver
biopsy tissue specimens were obtained from patients at
4 time points:
Time 1 (T1) - Initial inflammation phase: High HBV-
DNA load, a high HBsAg load, and serum ALT values
were no more than 5 times the upper limit of normal
(normal range: 10–40 IU/L).
Time 2 (T2) - Climax phase of inflammation: Reduced
viremia and ALT levels elevated to greater than 10
times the upper limit of normal (normal range:
10–40 IU/L).
Time 3 (T3) - Decline phase of inflammation: Serum
ALT levels decreased by greater than 50% of values in
the T2 phase.
Time 4 (T4) - Regression phase of inflammation: Serum
HBV-DNA decreased to the level less than 5× 103
copies/mL and serum ALT level less than 100 IU/L.
Hepatitis serology
HBsAg, anti-HBs, anti-HBc, HBeAg,anti-HBe, anti-HDV,
anti-HCV, and anti–HIV titers were measured using an
enzyme immunoassay kit. Serum HBV-DNA was quanti-
fied using a sensitive real-time polymerase chain reac-
tion (RT-PCR) technique.
Pentamers and PD1 analysis
The following antibodies were used for PBMC staining:
anti-CD8-FITC, anti-PD1-APC and anti-HLA-A2 (Bio
Table 1 Patients demographic data and levels of serum markers at time of initial presentation








1 male 200 527 1 × 107 positive
2 male 120 513 1.5 × 107 positive
3 male 135 468 6.3 × 106 positive
4 female 122 491 6.1 × 106 positive
5 male 150 132 8.7 × 106 positive
6 female 132 401 1.3 × 105 positive
7 female 197 401 5.1 × 106 positive
8 male 200 441 1.1 × 105 positive
9 male 101 356 7.5 × 104 positive
10 female 157 437 3.3 × 106 positive
11 male 156 491 2.0 × 105 positive
12 female 189 411 7.0 × 105 positive
13 female 172 328 5.4 × 106 positive
14 male 194 396 1.9 × 106 positive
15 female 200 567 1.1 × 107 positive
Abbreviations: ALT, alanine transaminase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HLA, human leukocyte antigen.
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T-cells were identified with human leukocyte antigen A2
(HLA-A2) pentamers containing core 18–27 peptide
(FLPSDFFPSV), evn 335–343 peptide (FLLTRILTI) and
pol 575–583 peptide (FLLSLGIHL), which were labeled
with the fluorochrome PE.
PBMCs from peripheral blood were incubated for
15 min at 37°C with 1 μg of PE-labeled pentamer complex
in PBS and then washed twice. Cells were then incubated
with saturating concentrations of directly conjugated anti-
CD8–FITC and PD1-APC mAb, for 15 min. After washing
the cells twice, they were analyzed immediately on a
FACSCalibur flow cytometer using Cell Quest software
(BD biosciences, East Rutherford NJUSA).
Lymphocytes were gated according to their physical
parameters. All patients were HLA-A2 positive.
Pentamer-positive responses are reported as the per-
centage of pentamer-positive T-cells among the total
CD8 population. Frequencies of pentamer-positive cells
in healthy control were not exceeding 0.08% of total cir-
culating CD8 cells. The expansion (n-fold) was calcu-
lated as the ratio of the percentage of pentamer-positive
T cells between the T1 and T2 periods.
B7H1 expression analysis
B7-H1 expression on circulating myeloid dendritic cells
(mDCs) was measured using 1 mL of fresh heparinized
peripheral blood. Cells were lysed with FACS lysing so-
lution (BD biosciences, East Rutherford NJUSA) to re-
move RBCs and then incubated with antibodies against
B7-H1-PE and CD11c-PEcy7 for 20 min at roomtemperature. After washing twice with PBS, the cells
were analyzed by flow cytometry on a FACSCalibur flow
cytometer (BD Biosciences).
Immunohistochemical staining
Acetone-fixed liver tissue cryosections (5 μm) were incu-
bated with anti–PD-1, anti–PD-L1 and anti-CD8 (Abcam
plc, Cambridge, UK) antibodies overnight at 4°C after
blocking endogenous peroxidase activity with 0.3% H2O2.
Positive cells (brown color) were counted in high power
fields (hpf) by 2 independent observers. PD-1 and PD-L1
immunofluorescence dual staining was performed. In
brief, liver tissues were incubated overnight with primary
antibodies at 4°C followed by secondary antibodies for
45 minutes at room temperature. Anti- PD-1 and PD-L1
(both diluted 1:50; Santa Cruz Biotechnology, Santa Cruz,
CA USA) and anti- CD8, CD68, CD31, CD11c and (all
diluted 1:50; Dako, Glostrup, Denmark) were used as pri-
mary antibodies. Fluorescein isothiocyanate– conjugated
immunoglobulin G and fluorochrome phycoerythrin -con-
jugated immunoglobulin G (Santa Cruz Biotechnology)
were used as secondary antibodies.
6. For RT-PCR, total RNA from liver biopsy tissue as
indicated was isolated using RNeasy kits (Qiagen, Venlo,
Netherlands). cDNA synthesis was performed using
SuperScript One-Cycle cDNA kit (Life Technologies,
Carlsbad, CA USA). The cDNA served as a template for
real-time PCR using Fast SYBR Green Master kit (Life
Technologies). The following primers for RT-PCR were
used: human IFNγ primers, 5´ -GCATCCAAAAGAGT
GTGGAG-3' (forward) and 5´-GCAGGCAGGACAACC
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CAAGCCTGTAGCC-3´ (forward) and 5´-GAGGACCT
GGGAGTAGATGA-3´ (reverse); and human glyceralde
hyde-3-phosphate dehydrogenase (GAPDH) primers,
5´ -AACAGCGACACCCACTCCTC−3´(forward) and
5´ -GGAGGGGAGATTCAGTGTGGT −3´(reverse). All
reactions were performed in triplicate. IFNγ and
TNFα mRNA expression of different group specimens
were normalized to glyceraldehydes 3-phosphate de-
hydrogenase (GAPDH). Relative mRNA levels are pre-
sented as unit values of 2-ΔΔCt, where Ct is the
threshold cycle value defined as the fractional cycle
number at which the target fluorescent signal passes
a fixed threshold above baseline.
Statistical analysis
The experimental data were analyzed using SPSS 13.0
software (IBM, Amonk, NY USA). Quantitative data are
described using mean± standard deviation (SD). Com-
parisons between groups were analyzed using variance
or nonparametric tests (Kruskal-Wallis and Mann–
Whitney U tests). p < 0.05 was considered significant.
Results
Clinical outcome
At baseline, all enrolled patients had high serum viral and
HBsAg loads. The highest HBV viral load was greater than
1.5 × 107 (copies/mL). The lowest HBV viral load was
greater than 1× 105 (copies/mL). The mean serum HBsAg
load of 15 patients was 433.6 ± 115.4 (ng/ml). During the
Climax phase of inflammation (T2), a significant increase
in serum ALT levels was paralleled by a profound decrease
in the serum HBV load in all patients. Ten of 15 patients
showed a low level of HBV-DNA replication from 5×103
to 1.5 × 104 copies/mL by the T4 period while five patients
had serum HBV-DNA less than 5× 103 copies/mL.
Longitudinal analysis of HBV-specific pentamer from T1
to T4
Multiple HBV-specific T cell responses were detected
throughout the clinical course from the T1 to the
T4 period. During the T1 period, the levels of core
18-27, env335-343 and pol575-583 were 0.69% ± 0.29%,
0.84%± 0.33% and 0.94%± 0.30% respectively; signifi-
cantly higher than the healthy control level (which never
exceeded 0.08%). During the T2 period, the frequency of
core18-27, env335-343 and pol575-583 further increased
significantly in all patients. Core 18–27 was detectable at
a frequency of 2.77% ± 0.45% of total circulating CD8+
cells (1300 core18-27 cells in 50,000 CD8+ cells), reach-
ing a frequency of 3.0% in 2 patients. The levels of
env335-343 and pol575-583 in CD8+ cells also increased
significantly, reaching the frequencies of 2.38%± 0.37%
(1200 env 335–343 cells in 50,000 CD8+ cells) and2.93%± 0.54% (1460 pol 575–583 cells in 50,000 CD8+
cells) respectively. During the decline phase of inflam-
mation (T3), the frequency of core18-27, env335-343
and pol575-583 in total circulating CD8+ cells were
decreased from 2.77%± 0.45% to 1.75%± 0.55%, from
2.38%± 0.37% to 1.88%± 0.55% and from 2.93% ± 0.54%
to 1.99%± 0.16% respectively. During the regression
phase of inflammation (T4), the frequency of these 3
pentamers further decreased to no more than 1% of total
circulating CD8+ cells (Figure 1, Figure 2, Figure 3A).
Longitudinal analysis of PD1 and PD-L1 expression from
T1 to T4 in patients with chronic hepatitis B
The frequency of PD1 and PD-L1 expression on circulat-
ing CD8+ T cells and mDCs respectively were detected
from the T1 to T4 periods. From T1 to T2, the propor-
tion of PD1 positive cells increased significantly from
13.1%± 4.2% to 35.7%± 5.8% of total circulating CD8+
cells. During the T3 period, the proportion of PD1-
positive cells decreased significantly from 35.7%± 5.8%
in the T2 period to 23.2%± 4.05% of total circulating
CD8+ T cells. During the T4 period, the proportion of
PD1-positive cells further decreased to 13.4%± 3.0%,
which approaches the levels found in the T1 period
(Figure 4A, Figure 3C). The frequency of PD1 expression
on pentamers was significantly higher than that among
total circulating CD8+ T cells. During T2 period the
frequency of PD1 expression on pentamers of core
18-27, env335-343 and pol575-583 were 57.5%± 13.6%,
54.2%± 5.6% and 53.3% ± 7.5% respectively (Figure 4B,
Figure 5).
The dynamic PD-L1 expression was also detected
on circulating CD11c +mDCs from the T1 to the T4
period. The level of PD-L1 expression on CD11c + cells
increased significantly after the onset of liver inflamma-
tion. The highest frequencies of PD-L1and CD11c dual
positive cells were found during the T2 period. Follo-
wing T2, the frequency of PD-L1and CD11c dual-
positive cells decreased progressively from 40.1% ± 5.82%
in T2 to28.86 ± 4.95% in T3 period. During T4, PD-L1
expression levels further decreased to11.2%± 3.54%,
which was lower than the levels detected in the T1
period (Figure 4C, Figure 3C).
Longitudinal analysis of intrahepatic CD8, PD-1and PD-L1
expression from T2 to T4
Serially sectioned liver biopsy specimens of enrolled
patients from periods T2 to T4 period were examined
for CD8, PD1 and PD-L1 expression by immunohisto-
chemistry. During the T2 period, CD8+ positive cells
infiltrated the portal tract and extend into the liver par-
enchyma. The number of infiltrating CD8+ positive cells
decreased from 328 ± 58/ hpf in T2 to 186 ± 21/hpf in
T3 period. During regression phase of inflammation
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Figure 1 Representative dot plots of pentamer staining for patients in T1, T2, T3 and T4 sequence. Fresh heparinized peripheral blood
samples were lysed with FACS lysing solution and then incubated with antibodies against pentamers and CD8-FITC for 20 min at 4°C. The
numbers in the upper right quadrants indicate the frequency of pentamers in total circulating CD8+ cells.
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lobular area, most aggregated in fibrous septa (Figure 6,
Figure 3D).
Using serial section, intra-hepatic PD1 and PD-L1 ex-
pression was also detected dynamically by immunohis-
tology. During the T2 period, PD1 and PD-L1 positive
cells were abundantly observed in periportal and lobular
areas of the liver. During the T3 period, the numbers of
PD1 and PD-L1 positive cells in the liver lobe areaFigure 2 The numbers of core-, env- and pol-PE positive cells
in 50000 CD8+ cells were compared betweemT1,T2,T3 and T4.
The number of core, env and pol increased significantly from T1 to
T2, and decreased progressively from T2 to T4. core, env and pol,
n = 15, P T1 vs T2 <0.01, P T2 vs T3 <0.05, P T3 vs T4 < 0.01.decreased significantly. The mean number of infiltrating
PD1 positive cells decreased from 388 ± 122/ hpf in T2
to 174 ± 53/ hpf in T3. The number of infiltrating
PD-L1-positive cells also decreased from 250 ± 92 / hpf
in T2 to 103 ± 14 in T3. In T4, PD1 positive cells were
almost absent in the lobular region, with most observed
in fibrous septa and the portal tract, while PD-L1-
positive cells were also frequently observed in the lobu-
lar region of the liver. The number of PD-L1 positive
cells decreased from 103 ± 14/hpf in T3 to92 ± 13/hpf in
T4. There was no significant difference between the
number of PD-L1-positive cells in T3 and T4 (Figure 6,
Figure 3D).
Co-localization of intra-hepatic PD-L1 with various cell
markers in T4
tlsb19ptThe number of intra-hepatic PD-L1 positive cells
did not decrease significantly from T3 to T4 period. Im-
munofluorescence double staining of liver tissue from
the T4 period showed that PD-L1 was primarily
expressed on CD68-positive macrophages (Kupffer cells),
and CD31-positive sinusoidal epithelial cells (Figure 7A).
Intra-hepatic PD-L1 expression on CD11c + cells was






















Figure 3 Correlation between PD1, PD-L1 expression and serum pentamer frequency, ALT level, HBsAg and HBV-DNA load.
(A) Percentage of core, even and pol from T1 to T4. The frequency of pentamers including core 18–27, even 335–343 and pol 575–583 increased
upon initial of inflammation (T1), reached peak level during climax of inflammation (T2) and decreased gradually during regression of
inflammation (T4). (core, even and pol, n = 15, P T1 vs T2 <0.01, P T2 vs T3 <0.05, P T3 vs T4 < 0.01) (B) Fluctuation of sALT, HBsAg and HBV-DNA from
T1 to T4. From T1 to T2, serum ALT level increased significantly, in parallel with pentamer cells clonal expansion, and decreased significantly in
concordance with pentamer cells clonal contraction from T3 to T4. ( sALT, n = 15, P T1 vs T2 <0.01, P T2 vs T3 <0.05, P T3 vs T4 <0.05) Serum HBsAg
and HBV-DNA load decreased during inflammation flare up period. (HBsAg and HBV-DNA copies, n = 15, P T1 vs T2 <0.01, P T2 vs T3 <0.01,
P T3 vs T4 < 0.01) (C) Percentage of circulating PD1 and PD-L1 from T1 to T4. From T1 to T2 period, in parallel with pentamer cells clonal
expansion, circulating PD1 and PD-L1 expression increased significantly. From T3 to T4 period, parallel with pentamer cells clonal contraction,
circulating PD1 and PD-L1 expression decreased significantly. (P T1 vs T2 <0.01, P T2 vs T3 <0.05, P T3 vs T4 < 0.01 n = 5) (D) The number of intra
hepatic CD8, PD1 and PD-L1 positive cells from T2 to T4. DuringT2 period, the number of intra-hepatic PD1, PD-L1 and CD8 reached the highest
level and they were decreased significantly in T3 period. From T3 to T4 period, number of intra-hepatic PD-1 and CD8 positive cells further
decreased significantly, however PD-L1 did not. (PD1,PD-L1 and CD8, PT2 vs T3 < 0.01; PD1 and CD8, P T3 vs T4 < 0.01; PD-L1, P T3 vs T4 > 0.05; n = 5).
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during T4, the majority of CD11c + cells did not
(Figure 7C). Because the frequency of PD-L1 expression
on circulating CD11c + cells decreased significantly from
T3 to T4 period, there is good concordance between
intra-hepatic and circulating PD-L1 expression on
CD11c + cells.
Dynamic analysis of TNF-α and IFN-γ mRNA expression
from T1 to T4
Pro-inflammatory cytokines expression levels were also
dynamically detected by real-time PCR in chronic
hepatitis B patients from T1 to T4 period. As shown in
Figure 8, TNF-α and IFN-γ mRNA can be detected in
patients in T1 period, and increased progressively,
reaching peak levels during the climax phase of inflam-
mation (T2) and decreasing rapidly during the decline
phase (T3). During T4, IFN-γ mRNA levels decreased to
less than those in the T1 period, while TNF-α mRNA
expression were at a relatively high level. The TNF-α
mRNA level further decreased from the T3 to the T4period, but was still significantly higher than the levels
found during T1 (Figure 8).
Correlation between PD1/ PD-L1 expression and
downstream inflammatory events
As shown in Figure 3, the circulating and intra-hepatic
PD1/PD1-L expression were correlated with downstream
inflammatory events, such as HBV-specific CD8 T cells
expansion and contraction, TNFα and IFNγmRNA ex-
pression and changes in serum HBV-DNA and ALT
levels.
The number of PD1 and PD-L1 positive cells, both
intra- and extra-hepatic increased significantly during
T2 compared to those in T1 period. In particular intra-
hepatic PD1- and PD-L1-positive cells infiltrated exten-
sively in the lobular and portal areas during T2. During
the same phase, the number of pentamers such as core
18–27, pol 575–583 and even 335–343 also peaked rap-
idly, reaching levels greater than 4, 3 and 3.2 times
higher than the levels in T1 respectively. Subsequently,



















Figure 4 (A) Representative dot plots of PD1 and CD8 double staining for patients in T1,T2,T3 and T4 sequence. Fresh heparinized
peripheral blood samples were lysed with FACS lysing solution and then incubated with antibodies against PD1-APC and CD8-FITC for 20 min at
4°C. The numbers in the upper right quadrants indicate the frequency of PD1 in total circulating CD8+ cells. (B) Representative dot plots of PD1
and pentamer double staining for patients in T2 period. Fresh heparinized peripheral blood samples were lysed with FACS lysing solution and
then incubated with antibodies against pentamer-PE and PD1-APC for 20 min at 4°C. The numbers in the upper right quadrants indicate the
frequency of PD1-APC in circulating core18-27, enve335-343 and pol575-583 cells. (C) Representative dot plots of PD-L1 and CD11c double
staining for patients in T1, T2, T3 and T4 sequence. Fresh heparinized peripheral blood samples were lysed with FACS lysing solution to remove
RBCs and then incubated with antibodies against PD-L1-PE and CD11c-PEcy7 for 20 min at 4°C. The numbers in the upper right quadrants
indicate the frequency of PD-L1 and CD11c dual positive cells.
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marked decrease in HBV-DNA and HBsAg. During this
period, TNFα and IFNγmRNA expression also reached
peak levels.
During T3 period, the serum HBV-DNA levels pro-
gressively decreased to levels less than 10-fold below
those found in T2, and serum HBsAg levels decreased
greater than 2-fold. At the meantime, the number of
pentamers, which include core18-27, even 335–343 and
pol 575–583 cells also decreased significantly, paralleling
the decrease of serum ALT, and intra-hepatic TNFα and
IFNγmRNA expression levels. Concomitant with these
changes, the levels of both the circulating and intra-
hepatic PD1 and PD-L1 expression also decreased
significantly.
During T4 period, serum HBV-DNA levels further
decreased. The serum ALT also further declined,approaching normal level (less than 100u/L). Correlating
very well with these changes, the frequency of circulat-
ing pentamers and the number of intra-hepatic CD8+
cells further decreased significantly and the intra-hepatic
IFN-γ mRNA expression level decreased to less than
that found in T1; however, TNFα mRNA maintained a
relatively high level throughout the same period. The
frequency of circulating PD1-positive cells decreased
near to T1 levels, and almost all of the liver infiltrating
PD1-positive cells aggregate in fibrous septa. It is noted
that during this period, the number of intra-hepatic PD-
L1-positive cells did not decrease significantly compared
to that during the T3 period (Figure 3 A,B,C,D).
Discussion
PD1, a negative regulator of the immune response, is
predominantly expressed on activated T cells [10,11].
Figure 5 The frequency of PD1 expression on pentamers in T2
compared with which expressed on circulating CD8. During T2
period, the frequency of PD1 expression on pentamers were higher
significantly than that of expressed on total circulating CD8 ( P core
vs CD8 <0.05, Penv vs CD8 <0.05, P pol vs CD8< 0.05 ).
Wenjin et al. BMC Gastroenterology 2012, 12:109 Page 8 of 11
http://www.biomedcentral.com/1471-230X/12/109PD-L1, the ligand for PD1, is induced on APCs upon
onset of activation [10,11]. The interaction between PD1
and PD-L1 transmits a co-inhibitory signal to down-
stream molecular events and then limits the activated
T cell proliferation and cytotoxic effects, resulting in
tissue protection against severe injury by an over-
vigorous immune response [12-14]. During the inflam-
mation flare up period in patients with chronic hepa-
titis B, the frequency of circulating PD1-positive cellsFigure 6 Immunohistochemical staining for intrahepatic CD8-positive
hepatitis B. Representative figures for patients in T2, T3 and T4 sequence. n
CD8-positive, PD-1-positive or PD-L1-positive cells infiltrated extensively in l
positive and PD-1-positive cells were less observed in lobular areas, while PDand the number of intra-hepatic PD1-positive cells
increased significantly and reached peak levels. During
the same phase, circulating and intra-hepatic PD-L1
expression also increased significantly. Activated HBV
specific T cells expressing PD1 were recruited to the
liver and contacted PD-L1 expressing APCs (e.g.
mDCs, kupffer cells, and LSECs). This interaction
resulted in impaired functions of HBV specific-T cells.
Kassel et al. reported that the upregulation of intra-
hepatic PD-L1 may efficiently limit over-vigorous im-
mune response, avoiding severe liver damage [14].
Chen et al. also reported that delayed PD1 up-
regulation in patients with acute hepatitis B is closely
associated with fulminant hepatitis[12].
Based on the Polly Matzinger’s viewpoint, the expres-
sion of co-inhibitory molecules is needed for the main-
tenance of homeostasis [15]. In chronic hepatitis B
patients, during the immune-inactive phase, whose liver
function was nearly normal, it is not necessary to in-
crease significantly for circulating and intra-hepatic PD1
and PD-L1 expression. Our previous studies revealed
that in chronic hepatitis B patients with immune-
inactive state, PD-L1 positive cells were almost absent in
liver lobe (data is not shown). Rachel Kassel et al.
also reported that PD1 and PD-L1 expression always
increased significantly in inflamed liver from chronic, PD-1-positive and PD-L1-positive cells in patients with chronic
= 5, High-power field, original magnification 400×. During T2 period,
iver tissue and they were decreased significantly in T3. In T4, the CD8-
-L1 positive cells were also frequently observed in liver lobular region.
Figure 7 (A) Co-localization of PD-L1 with CD31 and CD68 is shown by immunofluorescence double staining in liver biopsy specimens
of patients with hepatitis B in T4. PD-L1 (red) is co-localized with CD31 (green) positive endothelia cells or CD68 (green) positive Kupffer cells.
The 2-color merged panels show co-localization visible (yellow). Original magnification× 200. (B) Co-localization of PD-L1 and CD11c in liver tissue
from patients during T3. PD-L1 (red) is co-localized with CD11c (green). The 2-color merged panels show co-localization (yellow). Most
CD11c + cells expressed PD-L1. Original magnification × 200. (C) Co-localization of PD-L1 and CD11c in liver tissue from patients in T4. PD-L1 (red)
is co-localized with CD11c (green). The 2-color merged panels show co-localization (yellow). Most CD11c + cells did not express PD-L1. Only
CD11c + cells in the circle expressed PD-L1. Original magnification× 200.
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Although the up-regulation of PD1 and PD-L1 may
benefit restoration of liver function and maintenance of
homeostasis, it is also thought to facilitate replication of
remaining HBV, finally resulting in persistent infection. In
chronic hepatitis B patients, immune clearance phase and
immune inactive phase always displayed alternatively.
During the immune clearance phase, parallel with serum
ALT elevation, serum HBV-DNA and HBsAg load
declined, and may eventually lead to HBV-DNA seroclear-
ance and HBsAg seroconversion to its antibody (anti-HBs)
in part of patients; while following immune clearance
phase, most of the patients enter an immune inactive
phase with normal serum ALT, low serum HBV-DNA. In
immune inactive phase, HBV-DNA may replicate actively
again and HBV antigens may accumulated until it triggers
a next round of immune response against HBV.To elucidate the role of PD1 and PD-L1 in the mech-
anism of these two distinct states alternation, PD1 and
PD-L1 expression were analyzed longitudinally in
present study throughout the immune clearance phase;
and the changes of PD1 and PD-L1 expression were
related to HBV -specific T-cell clonal expansion, proin-
flammatory cytokine expression, serum ALT, HBV-DNA
and HBs-Ag fluctuation.
During the T2 phase, HBV specific T cells, including
core 18–27, even353-341 and pol 575–583, expanded
rapidly reaching the levels more than 35, 30, 37 times
higher than healthy control level (which never exceeded
0.08%), respectively. Concomitant with HBV- specific T-
cell clonal expansion, serum ALT reached the peak
levels, followed by a significant decreased in serum
HBV-DNA and HBsAg load. During this period, the per-
centage of PD1 expression of total CD8 cells increased
Figure 8 Detection of TNF-α and IFN-γ mRNA expression by
QT-PCR (n = 5). The levels of TNF-α and IFN-γ mRNA expression
significantly increased from T1 to T2, and decreased from T2 to T4.
TNF-α expression level in T4 period was still significantly higher than
that in T1. TNF-α mRNA was 2.5-fold higher in T4 than that in T1.
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phase. The frequency of PD1 expression on pentamers
was greater than 50% in the T2 phase.
During the T3 phase, the frequency of HBV-specific
CD8+T-cells decreased significantly, serum ALT level
decreased by more than half of that in the T2 period,
followed by further viremia reduction. During this
period, the frequency of circulating PD1 expression fur-
ther decreased significantly.
In T4, serum HBV-DNA further decreased to levels
lower than those found in T3 and serum ALT level
decreased to less than 100 IU/L. The frequency of HBV-
specific CD8+T-cells further decreased to less than
1.0% and the frequency of circulating PD1 expression
also decreased to less than the level found in T1.
Intra-hepatic PD1 expression was detected throughout
the clinical course from T2 to T4. In the T2 phase,
CD8+ and PD1+ cells infiltrated extensively in lobular
and portal areas. The number of infiltrating PD1-positive
cells decreased significantly from 388 ± 122/hpf in T2 to
174 ± 53/hpf in T3. In the T4, the number of intrahepatic
PD1+ cells further decreased significantly, and most
PD1-positive cells could be observed aggregated in fi-
brous septa and in periportal regions. Our previous find-
ings showed that almost all liver-infiltrating CD8 T-cells
expressed the home receptor CCR5 and CCR7 (data
is not shown). This phenomenon was consistent with
previous results that PD1-positive CD8 T-cells home
from peripheral circulation to lobular and portal areas to
form portal tract- associated lymphoid tissue. [16-18].
Two conclusions can be drawn based on these data.
First, CD8 T cells maintain normal proliferative capacity
towards HBV antigens and undergo colon expansion
during inflammatory episodes in patients with chronic
hepatitis B. Second, PD1 expression is located primarily
on activated HBV specific T cells and changes areassociated with HBV-specific T-cell clonal expansion
and contraction, serum ALT and viral load changes.
These data are in line with previous findings which
showed that PD1 expression is induced and up-
regulated significantly on activated HBV-specific CD8 T-
cells during colon expansion period [8,12,14].
PD-L1 expression exhibits a similar dynamic pattern
in patients with chronic hepatitis B. The expression of
PD-L1 on circulating CD11c +mDCs increased during
the initial phase of liver inflammation (T1) and reached
peak levels in parallel with up-regulation of the fre-
quency of PD1 expression on circulating CD8+ T cells in
the T2 period. In the T3 period, following a decline in
circulating PD1 expression, the frequency of PD-L1 ex-
pression also decreased significantly. In the regression
phase (T4), associated with the decline of PD1 expres-
sion, the frequency of circulating PD-L1 decreased fur-
ther, approaching to the levels in T1 period. These data
indicate that there is good concordance between circu-
lating PD-1 and PD-L1; it changes during the inflamma-
tion flare period.
Intra-hepatic PD-L1 expression was detected from T2
to T4 phases of chronic hepatitis B. During the climax
phase of inflammation (T2), intra-hepatic PD-L1 positive
cells were observed extensively in lobular areas. The
number of these cells decreased significantly in the
decline phase of inflammation (T3) compared to the
levels in T2. It did not decrease significantly from T3 to
T4 period although the frequency of circulating
PD-L1 decreased significantly from 28.86%± 4.95% to
11.18%± 3.54% in the same period. Note, in T3 period,
most of liver infiltrating CD11c + cells were PD-L1 posi-
tive, while in T4, intrahepatic PD-L1 positive cells were
CD68+ Kupffer and CD31+ endothelial cells, and the
majority of intrahepatic CD11c were PD-L1 negative.
Studies have reported that PD-L1 expression can be
induced by pro-inflammatory cytokines such as IFNγand
TNFα in an antigen-independent manner [19-22]. Dur-
ing the regression period (T4), the mRNA expression
level of TNFα was maintained at a higher level com-
pared to that during the T1 period. This result suggests
that in liver tissue, a relatively high level of TNFα
expression may attribute to intrahepatic PD-L1 up-regu-
lation in the T4 phase.
In conclusion, these results suggest that persistent up-
regulation of intra-hepatic PD-L1 on CD68 kupffer and
CD31 endothelia may constitute an immunosuppressive
microenvironment during the regression phase (T4).
The effects of PD1 expressing HBV-specific T-cells are
dampened when they home the liver and come in con-
tact with PD-L1-expressing CD68+ Kupffer and CD31+
endothelial cells. This may facilitate replication of
remaining HBV-DNA and finally lead to recurrence of
hepatitis.
Wenjin et al. BMC Gastroenterology 2012, 12:109 Page 11 of 11
http://www.biomedcentral.com/1471-230X/12/109Conclusion
In general, the levels of co-inhibitory molecules expres-
sion were increasing progressively in parallel with
ascending inflammation and were decreasing signifi-
cantly during inflammatory regression phase. Contrary
to this phenomenon, intra-hepatic PD-L1 expression on
non-parenchyma cells did not decrease significantly in
inflammatory regression phase. This may contribute to
constitute immunosuppressive microenvironment which
may damp HBV-specific immune response and finally
lead to persistent HBV infection.
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